Tyler Van Buren
Stock Analyst at TD Cowen
(3.21)
# 2,553
Out of 5,182 analysts
65
Total ratings
48.08%
Success rate
3.2%
Average return
Main Sectors:
Stocks Rated by Tyler Van Buren
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $880 → $960 | $744.44 | +28.96% | 8 | Apr 23, 2026 | |
| SLNO Soleno Therapeutics | Downgrades: Hold | $85 → $53 | $52.75 | +0.47% | 2 | Apr 7, 2026 | |
| BHVN Biohaven | Maintains: Buy | $15 → $30 | $9.59 | +212.83% | 4 | Mar 11, 2026 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $30 → $35 | $23.42 | +49.44% | 1 | Feb 26, 2026 | |
| CRSP CRISPR Therapeutics AG | Maintains: Hold | $40 → $45 | $50.99 | -11.75% | 3 | Feb 13, 2026 | |
| CCCC C4 Therapeutics | Initiates: Buy | n/a | $2.83 | - | 1 | Dec 2, 2025 | |
| MBX MBX Biosciences | Initiates: Buy | n/a | $31.97 | - | 1 | Nov 4, 2025 | |
| TVTX Travere Therapeutics | Maintains: Buy | $30 → $40 | $40.81 | -1.98% | 2 | Oct 31, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Buy | $60 → $95 | $74.52 | +27.48% | 2 | Oct 30, 2025 | |
| GILD Gilead Sciences | Maintains: Buy | $115 → $125 | $127.75 | -2.15% | 6 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $29.48 | - | 1 | Jul 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $66.82 | - | 1 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $11.01 | - | 2 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $22.48 | - | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $76.39 | - | 1 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $70 → $60 | $48.70 | +23.20% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $10.75 | - | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $7.07 | - | 1 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $28.75 | - | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $30.45 | - | 1 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $71.90 | - | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $115.07 | - | 1 | Oct 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $86.49 | - | 1 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.31 | - | 2 | Jan 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $70 | $28.56 | +145.10% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $4.25 | - | 1 | Jul 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $10.29 | - | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $36.92 | - | 1 | Oct 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $225 | $25.15 | +794.63% | 1 | Feb 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $875 | $6.43 | +13,508.09% | 1 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $16.49 | +142.57% | 1 | Aug 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $30 | $16.81 | +78.47% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $50 | $1.21 | +4,032.23% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $0.35 | +8,508.32% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $14.74 | - | 1 | Nov 2, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $31.26 | - | 1 | Aug 4, 2017 |
Regeneron Pharmaceuticals
Apr 23, 2026
Maintains: Buy
Price Target: $880 → $960
Current: $744.44
Upside: +28.96%
Soleno Therapeutics
Apr 7, 2026
Downgrades: Hold
Price Target: $85 → $53
Current: $52.75
Upside: +0.47%
Biohaven
Mar 11, 2026
Maintains: Buy
Price Target: $15 → $30
Current: $9.59
Upside: +212.83%
Arcutis Biotherapeutics
Feb 26, 2026
Maintains: Buy
Price Target: $30 → $35
Current: $23.42
Upside: +49.44%
CRISPR Therapeutics AG
Feb 13, 2026
Maintains: Hold
Price Target: $40 → $45
Current: $50.99
Upside: -11.75%
C4 Therapeutics
Dec 2, 2025
Initiates: Buy
Price Target: n/a
Current: $2.83
Upside: -
MBX Biosciences
Nov 4, 2025
Initiates: Buy
Price Target: n/a
Current: $31.97
Upside: -
Travere Therapeutics
Oct 31, 2025
Maintains: Buy
Price Target: $30 → $40
Current: $40.81
Upside: -1.98%
BridgeBio Pharma
Oct 30, 2025
Maintains: Buy
Price Target: $60 → $95
Current: $74.52
Upside: +27.48%
Gilead Sciences
Oct 23, 2025
Maintains: Buy
Price Target: $115 → $125
Current: $127.75
Upside: -2.15%
Jul 22, 2025
Initiates: Buy
Price Target: n/a
Current: $29.48
Upside: -
Jan 7, 2025
Initiates: Buy
Price Target: n/a
Current: $66.82
Upside: -
Dec 12, 2024
Downgrades: Hold
Price Target: n/a
Current: $11.01
Upside: -
Oct 8, 2024
Initiates: Buy
Price Target: n/a
Current: $22.48
Upside: -
Sep 16, 2024
Initiates: Buy
Price Target: n/a
Current: $76.39
Upside: -
Sep 13, 2024
Maintains: Hold
Price Target: $70 → $60
Current: $48.70
Upside: +23.20%
Aug 13, 2024
Initiates: Buy
Price Target: n/a
Current: $10.75
Upside: -
Aug 6, 2024
Initiates: Buy
Price Target: n/a
Current: $7.07
Upside: -
Jun 24, 2024
Initiates: Buy
Price Target: n/a
Current: $28.75
Upside: -
May 15, 2024
Initiates: Buy
Price Target: n/a
Current: $30.45
Upside: -
Nov 29, 2023
Initiates: Outperform
Price Target: n/a
Current: $71.90
Upside: -
Oct 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $115.07
Upside: -
Aug 8, 2023
Initiates: Outperform
Price Target: n/a
Current: $86.49
Upside: -
Jan 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $1.31
Upside: -
Aug 8, 2022
Initiates: Outperform
Price Target: $70
Current: $28.56
Upside: +145.10%
Jul 12, 2022
Initiates: Outperform
Price Target: n/a
Current: $4.25
Upside: -
Dec 7, 2021
Initiates: Outperform
Price Target: n/a
Current: $10.29
Upside: -
Oct 11, 2021
Initiates: Outperform
Price Target: n/a
Current: $36.92
Upside: -
Feb 10, 2021
Initiates: Overweight
Price Target: $225
Current: $25.15
Upside: +794.63%
Nov 10, 2020
Initiates: Overweight
Price Target: $875
Current: $6.43
Upside: +13,508.09%
Aug 18, 2020
Initiates: Overweight
Price Target: $40
Current: $16.49
Upside: +142.57%
Aug 10, 2020
Maintains: Overweight
Price Target: $35 → $30
Current: $16.81
Upside: +78.47%
Jun 29, 2020
Initiates: Overweight
Price Target: $50
Current: $1.21
Upside: +4,032.23%
Apr 22, 2020
Initiates: Overweight
Price Target: $30
Current: $0.35
Upside: +8,508.32%
Nov 2, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $14.74
Upside: -
Aug 4, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $31.26
Upside: -